Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer
June 18 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Announces the Appointment
of
James Veltmeyer, MD as Chief
Medical Officer
Oceanside, CA
-- June
18, 2018
--
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) previously
announced
their
plans
to provide access to its
clinical stage cancer immunotherapy product StemVacs under
the Right To Try law
signed by President Trump on May 30th 2018,
and have
appointed Dr. James Veltmeyer as Chief
Medical
Officer
of their
future planned
cancer
clinic.
"Having
Dr.
Veltmeyer head up our
future "Right
To
Try
Cancer Clinic", as well as all
other clinical programs underway is a dream come true
for TSOI," said Timothy Dixon,
President, and CEO of Therapeutic Solutions International.
"In his role as
Chief of
the Department of Family Medicine at Sharp
Grossmont
Hospital,
where
he currently
provides
senior leadership to over 200 physicians,
Dr. Veltmeyer has developed skills that few ever do, allowing him
to bring a wealth of experience in management and medicine to
bear on our
programs. He is one of the
most compassionate doctors
I have ever known
and
he
will be
an amazing Chief Medical
Officer to oversee
our
future clinic where we plan to treat the most critically ill among
us, end-stage cancer patients," added Mr.
Dixon.
"The future of
medicine is unfolding right before our
eyes at a very rapid pace.
Cellular immunotherapies, such as the Company's StemVacs platform
allow for reprogramming of the immune system to selectively attack
the cancer stem cell, which is believed to be the root of tumor
formation," said
Dr. James
Veltmeyer. "Having worked with the team at TSOI since
joining their Scientific
Advisory Board, I have been
impressed at the Company's pragmatic approach towards
hyper-accelerated
therapeutics
development. I look forward to my more involved role in leading
clinical translation of the Company's discoveries from Bench to
Bedside."
"There are very few
people I know who can transition seamlessly from business to
medicine, to basic research," said Thomas Ichim,
Ph.D., Director of TSOI.
"I have
worked closely with Dr. Veltmeyer both at TSOI, and
as
well on his
Congressional Campaign. Dr. Veltmeyer is a
naturally born leader that cares #1 about patients. I look forward
to working alongside Dr. Veltmeyer in transforming the future
of medicine" added Dr.
Ichim.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jul 2023 to Jul 2024